GlassScriptPhysician profile
Paolo C Champion
NPI 1982670998
$13,464.12
in general payments reported to CMS, 2019-2025
42 companies · $7,007 in 2025
The $7,007 reported for 2025 was more than what 92% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,664 · 2020: $936 · 2021: $289 · 2022: $1,310 · 2023: $1,246 · 2024: $1,012 · 2025: $7,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $5,143 · Food and Beverage: $4,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $5,142.85 |
| Food and Beverage | $4,121.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hmu Consumables, LLC | $5,142.85 | 2025 | Dornier Medtech |
| Boston Scientific Corporation | $2,652.24 | 2019-2025 | Spaceoar Vue System - 10ml, Ams 700, Tactra |
| Neotract INC. | $638.59 | 2020 | |
| Janssen Biotech, INC. | $557.15 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Pfizer INC. | $507.71 | 2019-2025 | |
| Procept Biorobotics Corporation | $487.48 | 2022-2024 | Aquabeam Robotic System, Aquabeam System |
| Telix Pharmaceuticals | $252.20 | 2025 | Illuccix |
| Astellas Pharma US INC | $243.65 | 2019-2025 | Xtandi, Padcev |
| Myriad Genetic Laboratories, INC. | $232.21 | 2020-2025 | Prolaris |
| Tolmar Pharmaceuticals, INC. | $223.25 | 2020-2022 | |
| Progenics Pharmaceuticals, INC. | $213.85 | 2023-2025 | Pylarify |
| Dendreon Pharmaceuticals LLC | $205.04 | 2019-2025 | Provenge |
| Ferring Pharmaceuticals INC. | $193.28 | 2019-2020 | |
| Angiodynamics, INC. | $162.38 | 2023-2024 | Nanoknife |
| Bayer Healthcare Pharmaceuticals INC. | $161.96 | 2021-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $146.49 | 2023 | Itind System |
| Coloplast Corp | $144.11 | 2022 | |
| Endo Pharmaceuticals INC. | $140.03 | 2019-2022 | |
| Tolmar, INC. | $101.44 | 2023-2025 | Jatenzo, Eligard |
| Tempus Ai, INC | $100.00 | 2024 | |
| Abbvie INC. | $86.35 | 2022-2025 | |
| Ambu INC. | $82.28 | 2021-2025 | |
| Allergan, INC. | $75.95 | 2019-2021 | |
| Accord Healthcare, INC. | $70.83 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $64.30 | 2022-2024 | Keytruda |
| Healthtronics Stone Solutions, LLC | $48.54 | 2024 | Dornier Medtech |
| Laborie Medical Technologies Corp. | $48.42 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Endo USA, INC. | $47.50 | 2024-2025 | Aveed, Xiaflex |
| Convatec INC. | $45.80 | 2023 | |
| Antares Pharma, INC. | $40.22 | 2020-2021 | |
| Amgen INC. | $40.14 | 2020-2021 | |
| Biotissue Holdings INC. | $40.04 | 2022 | |
| Verity Pharmaceuticals INC. | $37.77 | 2025 | Tlando, Trelstar |
| Sumitomo Pharma America, INC. | $35.15 | 2023 | Gemtesa |
| Medtronic, INC. | $35.04 | 2024 | Interstim |
| Cook Medical LLC | $34.30 | 2019 | |
| Baxter Healthcare | $25.39 | 2023 | Tisseel |
| 180 Medical, INC. | $24.67 | 2024 | |
| Travere Therapeutics, INC. | $19.46 | 2019 | |
| Steris Corporation | $19.13 | 2024 | |
| Aytu Biopharma, INC. | $18.52 | 2019 | |
| Axonics, INC. | $18.41 | 2023 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,814.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paolo Champion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.